Iris Parent Holding Corp. (LIMNW)
Market Closed
30 Sep, 08:00 PM
NASDAQ (CM) NASDAQ (CM) Primary $
0. 06
+0.01
+24.7191%
$
1.49M Market Cap
- P/E Ratio
- Div Yield
1,214 Volume
- Eps
$ 0.04
Previous Close Investors:
Want to track LIMNW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
LIMNW closed today higher at $0.06, an increase of 24.7191% from yesterday's close, completing a monthly decrease of -30.0126% or -$0.02. Over the past 12 months, LIMNW stock gained 52.4725%.
LIMNW is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
Iris Parent Holding Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| VL Vincent Leva Linden Advisors LP | 268,199 | $64,340.94 | $11,934.86 | -$52,406.08 | -81.45% |
 Mikhail Shilshtut Limestone Investment Advisors LP | 22,562 | $5,413 | $1,004.01 | -$4,408.99 | -81.45% |
Iris Parent Holding Corp. (LIMNW) FAQ
What is the stock price today?
The current price is $0.06.
On which exchange is it traded?
Iris Parent Holding Corp. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is LIMNW.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.49M.
Has Iris Parent Holding Corp. ever had a stock split?
No, there has never been a stock split.
Iris Parent Holding Corp. Profile
| Biotechnology Industry | Healthcare Sector | Chris Kim CEO | NASDAQ (CM) Exchange | 53271X116 CUSIP |
| US Country | 1 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Liminatus Pharma, Inc. is an innovative company operating in the clinical-stage segment of the biopharmaceutical sector. Specializing in immuno-oncology, Liminatus Pharma focuses its efforts on the development of novel therapies aimed at combatting various forms of cancer. Based in La Palma, California, the company combines cutting-edge research with clinical trials to bring advanced treatment options to patients suffering from cancer. Through its commitment to understanding the complexities of tumor immunology, Liminatus Pharma strives to improve outcomes and enhance the quality of life for cancer patients globally.
Products and Services
- Immuno-Oncology Therapeutics: Liminatus Pharma is at the forefront of developing innovative immuno-oncology therapies that harness the power of the body's immune system to fight cancer. These therapies are designed to enhance patients' immune responses against tumors, potentially leading to more effective and targeted treatments.
- Clinical Trials and Research: The company actively conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates. Through rigorous testing and research processes, Liminatus Pharma aims to bring valuable data to the medical community that can guide future cancer treatment strategies.
- Collaboration with Research Institutions: Liminatus Pharma collaborates with various research institutions and universities to leverage collective expertise and resources in the field of immuno-oncology. These partnerships foster the development of groundbreaking therapies and promote scientific innovation.
- Patient Support Programs: Understanding the challenges faced by cancer patients, Liminatus Pharma offers support programs aimed at educating patients and their families about available treatment options. These programs help navigate the complexities of cancer care and provide resources to manage the treatment journey.
- Preclinical Development Services: In addition to its clinical-stage products, Liminatus Pharma offers preclinical development services that assist in the formulation and optimization of new therapeutic candidates. This service ensures that potential therapies are rigorously evaluated before advancing to clinical trials.
Contact Information
Address: 12611 Hiddencreek Way
Phone: 213 273 5453
Website: https://liminatuspharma.com
